Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: naturally (100), normally (347), usually (759)

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory follic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy for previously
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

Rituximab (12 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Lymphoma as maintenance monotherapy for relapsed stage
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

Obinutuzumab_maintenance

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Obinutuzumab (Maintenance) Regimen • NHL – Obinutuzumab (Maintenance) Indication • Obinutuzumab in combination with bend
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Obinutuzumab-maintenance.pdf

Ipilimumab Ver 1

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf

Chlorambucil_7_Rituximab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (7 day)-Rituximab Regimen • CLL – Chlorambucil (7 day)-Rituximab Indication • Treatment of CLL in elderl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-7-Rituximab.pdf

Chlorambucil_14_Rituximab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Chlorambucil (14 day)-Rituximab Regimen • CLL – Chlorambucil (14 day)-Rituximab Indication • Treatment of CLL in elde
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Rituximab.pdf

R&D public engagement and participation strategy

Description: University Hospital Southampton NHS Foundation Trust public engagement and participation strategy Executive summary This strategy outlines the aims, approac
Url: /Media/Southampton-Clinical-Research/PPI/RD-public-engagement-and-participation-strategy.pdf

WGLS (combined) user handbook

Description: University Hospital Southampton NHS Foundation Trust DOC987 Revision 1/ WRGL 33687 V1.0 Wessex Genomics Laboratory Service Wessex Genomics Laboratory Service (WGLS
Url: /Media/UHS-website-2019/Docs/Services/Pathology/WGLS-combined-user-handbook.pdf

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description: Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Indicat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

51 to 60 of 179

Previous … 4 5 6 7 8 … Next